Novartis Ag

Novartis Pharma Gmbh

Phil Lowe

Hermann Gram

Thomas Jung

Timothy Wright

Trevor Mundel

This invention relates to methods employing IL-1&#x3b2;-ligand/IL-1 receptor disrupting compounds (herein referred to as 'IL-1beta Compounds'); such as small molecular compounds disrupting IL-1&#x3b2; ligand-IL-1 receptor interaction, IL-1&#x3b2; antibodies or IL-1 receptor antibodies, e.g. IL-1&#x3b2; binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1&#x3b2; binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1&#x3b2; ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Growing community of inventors

Basel, Switzerland

Phil Lowe